Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial
eClinicalMedicine (2021) - Comments
pubmed: 34723164  doi: 10.1016/j.eclinm.2021.101169  issn: 2589-5370 

Sergey V Zhuravel, Oleg K Khmelnitskiy, Oleg O Burlaka, Alexey I Gritsan, Boris M Goloshchekin, Seieun Kim, Ka Young Hong